论文信息 - Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031 - 字舞流文

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

S. Raimondi | S. Meshinchi | T. Alonzo | R. Gerbing | M. Loken | J. Choi | B. Hirsch | P. Brown | R. Aplenc | L. Sung | J. Levine | E. Fox | S. Kahwash | A. Gamis | J. Pollard | B. Fisher | Katherine Tarlock | A. Wood | A. Kolb